A Phase 3, randomized, open-label study of belantamab mafodotin administered in combination with lenalidomide and dexamethasone [BRd] versus daratumumab, lenalidomide, and dexamethasone [DRd] in participants with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (NCT06679101)

The study will evaluate if belantamab mafodotin, lenalidomide and dexamethasone prolongs progression-free overall survival compared to daratumumab, lenalidomide and dexamethasone in participants with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.

Trial phase

Phase 3

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Dr Sueh-li Lim

Key inclusion data

Inclusion Criteria: At least 18 years old; Newly diagnosed multiple myeloma patient; Adequate organ function. Exclusion Criteria: No prior systemic therapy for multiple myeloma; Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent, or compliance with study procedures; Signs of meningeal or central nervous system involvement with multiple myeloma.